Cyfuse Biomedical K.K.

Tokyo Stock Exchange 4892.T

Cyfuse Biomedical K.K. Gross Profit Margin for the year ending December 31, 2023: 61.76%

Cyfuse Biomedical K.K. Gross Profit Margin is 61.76% for the year ending December 31, 2023, a -4.23% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Cyfuse Biomedical K.K. Gross Profit Margin for the year ending December 31, 2022 was 64.49%, a -19.96% change year over year.
  • Cyfuse Biomedical K.K. Gross Profit Margin for the year ending December 31, 2021 was 80.57%, a 65.27% change year over year.
  • Cyfuse Biomedical K.K. Gross Profit Margin for the year ending December 31, 2020 was 48.75%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
Tokyo Stock Exchange: 4892.T

Cyfuse Biomedical K.K.

CEO Ms. Shizuka Akieda
IPO Date Dec. 1, 2022
Location Japan
Headquarters Sumitomo Fudosan Mita Twin Building
Employees 21
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email